These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

931 related articles for article (PubMed ID: 31661636)

  • 21. Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor.
    Schneider EK
    Drug Metab Lett; 2018; 12(1):71-74. PubMed ID: 29595119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor.
    Rysgaard UK; Pedersen CL; Jensen JH; Sørensen L; Philipsen LKD; Leo-Hansen C; Olesen HV
    J Cyst Fibros; 2022 Sep; 21(5):844-849. PubMed ID: 35667973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Infectives Restore ORKAMBI
    Laselva O; Stone TA; Bear CE; Deber CM
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
    N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets.
    Evans IA; Sun X; Liang B; Vegter AR; Guo L; Lynch TJ; Zhang Y; Zhang Y; Yi Y; Yang Y; Feng Z; Park SY; Shonka A; McCumber H; Qi L; Wu P; Liu G; Lacina A; Wang K; Gibson-Corley KN; Meyerholz DK; Limoli DH; Rosen BH; Yan Z; Bartels DJ; Engelhardt JF
    JCI Insight; 2024 Apr; 9(8):. PubMed ID: 38646935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
    Paterson SL; Barry PJ; Horsley AR
    Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
    [No Abstract]   [Full Text] [Related]  

  • 31. Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.
    De la Hoz D; Villamil Osorio M; Restrepo-Gualteros SM
    Arch Argent Pediatr; 2019 Apr; 117(2):e131-e136. PubMed ID: 30869491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonology: CFTR modulators for cystic fibrosis.
    Bertoncini E; Colomb-Lippa D
    JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
    [No Abstract]   [Full Text] [Related]  

  • 37. Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells.
    De Santi C; Fernández Fernández E; Gaul R; Vencken S; Glasgow A; Oglesby IK; Hurley K; Hawkins F; Mitash N; Mu F; Raoof R; Henshall DC; Cutrona MB; Simpson JC; Harvey BJ; Linnane B; McNally P; Cryan SA; MacLoughlin R; Swiatecka-Urban A; Greene CM
    Mol Ther; 2020 Apr; 28(4):1190-1199. PubMed ID: 32059764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis.
    Yeh JT; Yu YC; Hwang TC
    J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.